Pfizer Trial Updates Test Investor Views On Pipeline And Valuation

Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment

Pfizer Inc. PFE shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the BRAFTOVI combination regimen for treating metastatic colorectal cancer.
Becker's Hospital Review

Pfizer gets FDA priority review for pediatric hemophilia treatment

Pfizer has received FDA priority review for a supplemental biologics license application to expand the indication of Hympavzi (marstacimab). The proposed label expansion would include patients with ...

Pfizer Secures $495 Million China Obesity Drug Deal

Pfizer (NYSE:PFE) is stepping deeper into the global weight loss race, striking a deal with Hangzhou Sciwind Bioscience for exclusive commercialization rights to ecnoglutide in mainland China, in an ...

Daiwa downgrades Pfizer (PFE) to neutral following full-year 2025 earnings

Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its ...
Becker's Hospital Review

Pfizer contemplates sale, spinoff of consumer health unit

The drug company on Tuesday said it launched a strategic review of Pfizer Consumer Healthcare, which sells common over-the-counter products like Advil, Centrum and ChapStick. “A range of options will ...

Pfizer nabs China obesity drug rights in $495 million deal

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...